Vimarsana
Biggest News Aggregation in the World

Page 2 - Pre Clinical Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pre Clinical Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pre Clinical Data Today - Breaking & Trending Today

Geron Corporation: Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3 - Vimarsana News

Geron Corporation: Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Published: May 11, 2023

Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong

Source: finanznachrichten.de
Related Topics:
France GeneralUnited StatesNicolas ChatainFaye FellerUwe PlatzbeckerValeria SantiniKaplan MeierAaron FeingoldMikkael SekeresNicolas ChapuisGeron Corporation NasdaqInternational Working GroupEuropean Hematology AssociationUniversity Hospital AachenUniversity Hospital Of LeipzigSylvester Comprehensive Cancer CenterExchange CommissionDrug AdministrationUniversity Of Florence School MedicineUniversity Of Miami Health SystemEastern TimeAnnual MeetingExecutive Vice PresidentChief Medical OfficerData Lower Risk Myelodysplastic Syndromes
Moderna, Inc.: Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age - Vimarsana News

Moderna, Inc.: Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Published: December 8, 2022

MRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron VariantAuthorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent VaccinesCAMBRIDGE, MA / ACCESSWIRE / December 8, 2022 / Moderna

Source: finanznachrichten.de
Related Topics:
United KingdomLavina TalukdarChris RidleyExchange CommissionModerna Inc ViewCorporate CommunicationsModerna IncDrug AdministrationPre Clinical DataChief Executive OfficerEmergency Use AuthorizationCoronavirus DiseaseVaccine Adverse Event Reporting SystemFact SheetsHealthcare Providers Administering VaccineVaccine ProvidersFull Prescribing InformationPrivate Securities Litigation Reform ActAnnual ReportQuarterly ReportVice PresidentInc View
Moderna, Inc.: Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age - Vimarsana News

Moderna, Inc.: Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age

Published: October 12, 2022

MRNA-1273.222 Targets the BA.4/BA.5 Strains of Omicron VariantAuthorization Is Based Upon Clinical and Pre-Clinical Data for Moderna's Bivalent Vaccine CandidatesCAMBRIDGE, MA / ACCESSWIRE / October 12

Source: finanznachrichten.de
Related Topics:
United KingdomElise MeyerLavina TalukdarExchange CommissionCorporate CommunicationsModerna IncDrug AdministrationPre Clinical DataBivalent VaccineChief Executive OfficerVaccine Adverse Event Reporting SystemPrivate Securities Litigation Reform ActAnnual ReportVice President
Investegate |Ultimovacs ASA Announcements | Ultimovacs ASA: Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development - Vimarsana News

Investegate |Ultimovacs ASA Announcements | Ultimovacs ASA: Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Published: April 8, 2022

Investegate announcements from Ultimovacs ASA, Ultimovacs Presents TET Platform Pre-Clinical Data at AACR 2022 Supporting Clinical Development

Source: investegate.co.uk
Related Topics:
United StatesNew OrleansNew Orleans Convention CenterMary Ann ChangOrleans Convention CenterAmerican Association For Cancer ResearchOslo University HospitalClinical DevelopmentUltimovacs PresentsPre Clinical DataTetanus Epitope TargetingAmerican AssociationCancer ResearchCarlos De SousaChief Executive OfficerMonday AprilExhibit Hallsd HPoster SectionUltimovac Tetanus Epitope TargetingAnn ChangInvestegate AnnouncementsInvestegate Company AnnouncementsUltimovacs AsaLobenewswire And Globenewswire